09/07/2026
Pancreatic cancer has long been one of the clearest examples of why patients desperately need research to create new options rather than simply variations of old ones. A drug targeting a pathway researchers once considered extremely difficult to drug has now moved from the laboratory → to clinical trials → to patients like Barbara → and finally to FDA approval.
This is what “research is turning hope into more time” actually looks like.
Read the article here: https://www.reuters.com/legal/litigation/revolution-medicines-gets-fda-nod-targeted-pancreatic-cancer-drug-2026-08-26/?utm_source=chatgpt.com